AbCellera Biologics Inc. (ABCL) Reports Q2 Loss, Misses Revenue Estimates

分组1 - AbCellera Biologics Inc. reported a quarterly loss of $0.13 per share, which was better than the Zacks Consensus Estimate of a loss of $0.15, but worse than the loss of $0.11 per share a year ago, indicating a 18.18% increase in loss year-over-year [1] - The company posted revenues of $7.32 million for the quarter ended June 2024, missing the Zacks Consensus Estimate by 27.71%, and down from $10.06 million in the same quarter last year [1] - AbCellera Biologics has underperformed the market, with shares down approximately 51.7% since the beginning of the year, contrasting with the S&P 500's gain of 8.7% [2] 分组2 - The current consensus EPS estimate for the upcoming quarter is -$0.15 on revenues of $11.03 million, and for the current fiscal year, it is -$0.57 on revenues of $43.13 million [4] - The Zacks Industry Rank for Medical - Biomedical and Genetics is in the top 37% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [5] - Kronos Bio, Inc., another company in the same industry, is expected to report a quarterly loss of $0.32 per share, which represents a year-over-year change of +38.5% [5]